Background: The creation of The Joint Commission primary stroke centers (PSCs) has increased access to acute stroke care in metropolitan areas. We hypothesized that the rise in PSCs in the Houston area was associated with demographic changes and decreased trial enrollment at our comprehensive stroke center.
Methods: Consecutive admissions to the UT Houston stroke team from January 2005 to June 2011 were reviewed for demographic and clinical information. Patient characteristics were compared across years. Logistic regression was performed to assess the odds of admission per year.
Results: During the 6.5-year study period, there were 6623 admissions. Admissions increased each year. The proportion of patients transferred from other hospitals to our Comprehensive Stroke Center increased from 24.6% in 2005 to 45.5% in 2011. The number of The Joint Commission PSCs in the greater Houston area increased from 2 to 15. The percentage of large artery occlusions fell from 32.9% in 2005 to a low of 16.4% in 2010, whereas minor strokes (National Institutes of Health Stroke Scale, 0-5) increased from 37.4% in 2005 to 48.6% in 2011. Among stroke patients presenting within 3 hours, study enrollment fell from 45.8% in 2005 to 19.3% in 2011.
Conclusions: We observed a temporal association between the changes in our patient demographics and the number of The Joint Commission PSCs in Houston. The number of large artery occlusions decreased over time, whereas the number of mild strokes increased. In addition, the number of patients enrolled into clinical trials substantially decreased. Increased access to stroke care at PSCs may be associated with changes in patient demographics and clinical trial enrollment at our center.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778254 | PMC |
http://dx.doi.org/10.1161/STROKEAHA.111.666156 | DOI Listing |
Alzheimers Dement
December 2024
Universidad Autónoma de San Luis Potosi, San Luis Potosi, SL, Mexico.
Background: Alzheimer's Disease (AD) is a neurodegenerative disease, characterized by a decrease in cognitive and behavioral functions of patients. Between the multiple potential disease-modifying therapeutics for AD, we have monoclonal antibodies as aducanumab, lecanemab, and donanemab. Recent results from the TRAILBLAZER-ALZ trial, highlighted donanemab as a promising monoantibodies treatment of early symptomatic AD.
View Article and Find Full Text PDFStroke Vasc Interv Neurol
November 2024
UCLA Comprehensive Stroke Center, Department of Neurology, University of California, Los Angeles, CA, USA.
Patient Prefer Adherence
January 2025
Department of Surgery & Cancer, Imperial College London, London, UK.
Statins are effective in reducing cardiovascular disease (CVD) risk, but adherence rates remain low globally. Understanding and addressing modifiable influences on adherence is key to improving outcomes. Existing reviews have methodological limitations, often failing to integrate qualitative and quantitative data or consider specific barriers to statin adherence.
View Article and Find Full Text PDFJMIR Cardio
January 2025
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Background: Stroke is a major cause of death and disability worldwide. Identifying individuals who would benefit most from preventative interventions, such as antiplatelet therapy, is critical for personalized stroke prevention. However, traditional methods for estimating treatment effects often focus on the average effect across a population and do not account for individual variations in risk and treatment response.
View Article and Find Full Text PDFSyst Rev
January 2025
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Background: The inadequate inclusion of sex and gender in medical research has resulted in biased clinical guidance and disparities in knowledge and patient outcomes. Despite efforts by regulatory and funding agencies, opportunities to generate sex-specific knowledge are frequently overlooked. While certain disciplines in cardiovascular medicine have made notable progress, these advances have yet to permeate the literature on perioperative cardiovascular complications in non-cardiac surgery.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!